Duchenne muscular dystrophy (DMD) is a devastating genetic disorder, whose management is still a major challenge, despite progress in genetic and pharmacological disease-modifying treatments have been made. Mitochondrial dysfunctions contribute to DMD, however, there are no effective mitochondrial therapies for DMD. SIRT1 is a NAD+-dependent deacetylase that controls several key processes and whose impairment is involved in determining mitochondrial dysfunction in DMD. In addition to well-known resveratrol, other potent selective activators of SIRT1 exist, with better pharmacokinetics properties and a safer profile. Among these, SRT2104 is the most promising and advanced in clinical studies. Here we unveil the beneficial effects of SRT2104 in flies, mice, and patient-derived myoblasts as different models of DMD, demonstrating an anti-inflammatory, anti-fibrotic, and pro-regenerative action of the drug. We elucidate, by molecular dynamics simulations, that a conformational selection mechanism is responsible for the activation of SIRT1. Further, the impact of SRT2104 in reshaping muscle proteome and acetylome profiles has been investigated, highlighting effects that mimic those induced by exercise. Overall, our data suggest SRT2104 as a possible therapeutic candidate to successfully counteract DMD progression.
Mitochondrial dysfunction is an early pathogenic event in dystrophic muscle contributing to muscle damage. Here, we provide an in-depth characterization of the marked induction of mitochondrial fission in mdx muscle fibers, driven by excessive activation of the fission regulator Drp1. This aberrant Drp1 activity triggers the integrated stress response (ISR), resulting in muscle-derived secretion of FGF21, which in turn promotes the fibro-adipogenic differentiation of fibro-adipogenic progenitors (FAPs). Importantly, we demonstrate that inhibition of Drp1 is both necessary and sufficient to restore mitochondrial function and suppresses FGF21 upregulation, limiting its detrimental impact on FAPs and contributing to the overall improvement of DMD phenotype. Our study identifies FGF21 as a key mediator of DMD pathology and supports targeting mitochondrial dynamics as a disease-modifying therapeutic strategy.